TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18-45 years~* At least moderate dental pain assessed by a categorical scale pain intensity scale and a score of at least 5 on the 11-point (0-10) pain intensity numerical rating scale (PI-NRS) following surgical removal of three third-molars~Exclusion Criteria:~* Subjects who are not otherwise healthy~* Test positive for the urine drug screen~* Taking prohibited medications will not be allowed to participate in this study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-10450232 250 mg (Type: EXPERIMENTAL): None
- JNJ-10450232 1000 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Acetaminophen 1000 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Suicide in the Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-~Patients must have:~Depressive symptoms and signs. (Required for 920 of the 1200 patients; 280 patients should have no significant depressive symptomatology.)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Weighing at least 40 kg~* Confirmed diagnosis of cystic fibrosis (CF) and G551D mutation in at least 1 allele~* Forced expiratory volume in 1 second (FEV1) of at least 40% of predicted normal for age, gender, and height~* Willing to remain on stable medication regimen for the duration of study participation~* No significant clinical laboratory abnormalities, not pregnant, and willing to use at least 2 highly effective birth control methods during Part 1 and 1 highly effective birth control method during Part 2 of the study~* No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator~Exclusion Criteria:~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject~* Ongoing acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 14 days of Day 1 of the study~* History of alcohol, medication or illicit drug abuse within one year prior to Day 1~* Abnormal liver function ≥ 3x the upper limit of normal~* History of abnormal renal function (creatinine clearance \< 50 mL/min using Cockcroft-Gault equation)~* History of solid organ or hematological transplantation~* Pregnant or breast-feeding (for women)~* Ongoing participation in another therapeutic clinical trial, or prior participation in an investigational drug study without appropriate washout~* Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP3A4)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ivacaftor Group A (Type: EXPERIMENTAL): Subjects in Part 1 who first received 25 mg or 75 mg of ivacaftor every 12 hours (q12h) for 14 days, then crossed over to receive the alternate dose for another 14 days.
- Ivacaftor Group B (Type: EXPERIMENTAL): Subjects in Part 1 who first received 75 mg or 150 mg of ivacaftor q12h for 14 days then crossed over to receive the alternate dose for another 14 days.
- Ivacaftor Group C (Type: EXPERIMENTAL): Subjects in Part 2 who received 150 mg or 250 mg of ivacaftor q12h for 28 days.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects who received placebo in Part 1 and subjects who received placebo in Part 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic or locally advanced, histologically documented TNBC characterized by absence of human epidermal growth factor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression~* No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC~* Eligible for taxane monotherapy (i.e., absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control)~* A representative formalin-fixed, paraffin-embedded tumor specimen in paraffin blocks, or at least 20 unstained slides with an associated pathology report documenting ER, PR, and HER2 negativity. Participants with fewer than 20 unstained slides available at baseline, and not fewer than 12 unstained slides will be eligible upon discussion with Medical Monitor~* Eastern Cooperative Oncology Group performance status of 0 or 1~* Measurable disease as defined by RECIST v1.1~* Adequate hematologic and end-organ function~Exclusion Criteria:~* Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases~* Leptomeningeal disease~* Pregnancy or lactation~* History of autoimmune disease~* Prior allogeneic stem cell or solid organ transplantation~* Positive test for human immunodeficiency virus~* Active hepatitis B or hepatitis C~* Receipt of a live, attenuated vaccine within 4 weeks prior to randomization, during treatment, or within 5 months following the last dose of atezolizumab/placebo

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab Plus Nab-Paclitaxel (Type: EXPERIMENTAL): Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
- Placebo Plus Nab-Paclitaxel (Type: PLACEBO_COMPARATOR): Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ketamine in Patients With Treatment-resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Be medically stable on the basis of clinical laboratory tests performed at screening~* Meet diagnostic criteria for recurrent major depressive disorder (MDD), without psychotic features~* Have a history of inadequate response, ie treatment was not successful, to at least 1 antidepressant~* Have an Inventory of Depressive Symptoms-Clinician rated, 30 item (IDS-C30) total score \>= 40 at screening and predose at Day 1~* Inpatient or agreed to be admitted to the clinic on each dosing day~Exclusion Criteria:~* Has uncontrolled hypertension~* Has a history of, or current signs and symptoms of diseases, infections or conditions that in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments~* Has known allergies, hypersensitivity, or intolerance to ketamine or its excipients~* Is unable to read and understand the consent forms and patient reported outcomes, complete study-related procedures, and/or communicate with the study staff

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Placebo 3 times/week (Type: PLACEBO_COMPARATOR): None
- Ketamine 3 times/week (Type: EXPERIMENTAL): None
- Ketamine 2 times/week (Type: EXPERIMENTAL): None
- Placebo 2 times/week (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Total Knee Arthroplasty: Functional and Clinical Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients requiring primary total knee replacement~2. Patients willing and able to comply with the follow-up visits and evaluations~3. Patients willing to sign informed consent approved by the Institutional Review Board~Exclusion Criteria:~1. Patients with inflammatory arthritis~2. Patients with diabetic neuropathy~3. Patients unable to ambulate without the use of an assistive device prior to surgery~4. Patients unable to stand in single limb stance on each foot prior to surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Stryker (Type: ACTIVE_COMPARATOR): Subjects will be receiving the Stryker Triathlon total knee replacement
- Zimmer (Type: ACTIVE_COMPARATOR): Subjects will be receiving a Zimmer NexGen total knee replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 6 and maximally 15 years of age~* Diagnosis of asthma and baseline lung function tests as determined by the protocol~* Has required and received treatment with inhaled corticosteroids within the timeframe and doses specified in the protocol~Exclusion Criteria:~* Severe asthma~* Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): budesonide/formoterol
- 2 (Type: ACTIVE_COMPARATOR): budesonide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OPALINE : A Study Of Morbidity And Mortality At 2 Years

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years of age;~* Patients treated with a targeted therapy (sunitinib, everolimus) or with other treatments (interferon, or metabolic radiotherapy, or chemotherapy or somatostatin analog)\* for:~  \*Patients whose treatment line (targeted therapy or other treatment) is initiated as a 1st, 2nd, 3rd or 4th line of therapy at the time of inclusion (incident patients) or patients receiving their 1st, 2nd, 3rd or 4th line of therapy provided that treatment was initiated in the site in which the patient is enrolled in the study (prevalent patients); a change of line is defined as a change in molecule or combination.~* A histologically confirmed unresectable or metastatic pancreatic neuroendocrine tumor;~* Well-differentiated;~* Progressive prior to initiation of treatment in the investigator's judgment (clinical or radiological progression);~* Patients who have been informed of the conditions of the study and who have signed the informed consent.~Exclusion Criteria:~* Patients with a diagnosis of poorly differentiated neuroendocrine carcinoma or an adenoneuroendocrine carcinoma.~* Patients receiving targeted therapy (everolimus or sunitinib) already received in a previous line of treatment (rechallenged patient).~* Patients refusing to give consent.~* Patients receiving a fifth line or subsequent line of systemic treatment.~* Patients participating in a clinical trial in a treatment arm not validated by the MA and the TNCD according to the version dated December 2013.~* Patients randomized to the placebo arm of a placebo-controlled trial or to a double-blind trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Sunitinib (Type: None): None
- Afinitor (Type: None): None
- other treatment (chémotherapy, SSA..) (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy men,~2. Age between 18 and 45 years~3. Normal weight (according to the table provided by Metropolitan Life Insurance).~Exclusion Criteria:~1. Hypersensitivity to opioids or naloxone,~2. History of addictive disease,~3. Significant cardiac, respiratory, gastrointestinal, neurological, dermatological, and psychiatric diseases,~4. Concurrent medication with an analgesic drug,~5. Student and employees affiliated with our laboratory

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Propranolol, Then Placebo (Type: ACTIVE_COMPARATOR): Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
- Placebo, Then Propranolol (Type: PLACEBO_COMPARATOR): Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female 18 years or older~* Clinically definite diagnosis of Tuberous Sclerosis Complex according to the modified Gomez criteria or sporadic LAM (biopsy-proven or compatible chest CT scan)~* Clinically definite diagnosis of renal angiomyolipoma~* At least one Angiomyolipoma of ≥ 3 cm in its longest diameter using CT or MRI~* Females of child bearing potential must use birth control and have documentation of negative pregnancy test~* Written informed consent according to local guidelines~Exclusion Criteria:~* Recent heart attack, cardiac related chest pain or stroke~* Severely impaired lung function~* Bleeding related to angiomyolipoma or embolization during 6 months prior to randomization~* Clinically significant chylous ascites~* Clinically significant hematological or hepatic abnormality~* Severe liver dysfunction~* Severe kidney dysfunction~* Pregnancy or breast feeding~* Current infection~* History of organ transplant~* Surgery within two months prior to study enrollment~* Prior therapy with a medication in the same class as Everolimus~* Recent use of an investigational drug~* Bleeding diathesis or on oral anti-vitamin K medication~* Uncontrolled high cholesterol~* Uncontrolled diabetes~* HIV~* Inability to attend scheduled clinic visits~* Patients with metal implants thus prohibiting MRI evaluations~* Angiomyolipoma which requires surgery at the time of randomization~* History of malignancy~* Severe or uncontrolled medical conditions which would cause an unacceptable safety risk or compromise compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Study drug was given by continuous oral daily dosing of two 5 mg tablets.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was given by continuous oral daily dosing of two 5 mg tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Echinacea Junior vs Vitamin C in Children 4-12 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 4-12 years~* written informed consent by parents and optionally by child~* daily Access to computer/email~* german language skills~Exclusion Criteria:~* 13 years or older, younger than 4 years~* participation in a clinical study during past 30 days~* intake of antimicrobial, antiviral, immunosuppressive substances, salicylic medicaments (like Aspirin)~* surgical intervention 3 months Prior to inclusion or planned intervention during the observation period~* known Diabetes mellitus~* known and treated atopy or Asthma~* cystic fibrosis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease (COPD)~* diseases of the immunosystem (like autoimmune disorders, degenerative illnesses (like AIDS or leucosis))~* Metabolic or Resorption disorders~* Liver or kidney diseases~* Serious health Problems (e.g. neurological Problems)~* known allergies against compositae (e.g. camomile or dandelion) or any of the substances of the investigational product

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Echinaforce Junior Tablets (Type: EXPERIMENTAL): Hydroalcoholic extract of Echinacea purpurea herb and radix
- Vitamin C Tablets (Type: ACTIVE_COMPARATOR): synthetically produced ascorbic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Men and women ≥ 18 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1~* Histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)~* Tumor progression or recurrence within 6 months of last dose of platinum therapy in the adjuvant (ie with radiation after surgery), primary (ie, with radiation), recurrent, or metastatic setting~* Measurable disease by Computed tomography (CT) or Magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria~Exclusion Criteria:~* Active brain metastases or leptomeningeal metastases are not allowed~* Histologically confirmed recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary, and salivary gland or non-squamous histologies (eg: mucosal melanoma) are not allowed~* Subjects with active, known or suspected autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Nivolumab (Type: EXPERIMENTAL): Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
- Arm B: Cetuximab/Methotrexate/Docetaxel (Type: ACTIVE_COMPARATOR): Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression~OR~Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression~OR~Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete